<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4568</journal-id>
<journal-title><![CDATA[Enfermería Actual de Costa Rica]]></journal-title>
<abbrev-journal-title><![CDATA[Enfermería Actual de Costa Rica]]></abbrev-journal-title>
<issn>1409-4568</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Costa Rica ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-45682018000200185</article-id>
<article-id pub-id-type="doi">10.15517/revenf.v0i35.34097</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de la amikacina como profilaxis en pacientes sometidos a prostatectomía]]></article-title>
<article-title xml:lang="en"><![CDATA[Use of amikacin as prophylaxis in patients undergoing prostatectomy]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso de amicacina como profilaxia em pacientes submetidos à prostatectomia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quesada Mora]]></surname>
<given-names><![CDATA[Ana Gisella]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Campos]]></surname>
<given-names><![CDATA[Seidy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brenes Campos]]></surname>
<given-names><![CDATA[Geovanna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Dr. Carlos Luis Valverde Vega  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Dr. Carlos Luis Valverde Vega  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<numero>35</numero>
<fpage>185</fpage>
<lpage>200</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-45682018000200185&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-45682018000200185&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-45682018000200185&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El objetivo de este artículo es presentar la mejor evidencia científica disponible sobre el uso de la amikacina como profilaxis en pacientes sometidos a prostatectomía. La indicación de amikacina en cirugías tipo prostatectomías se remite al uso profiláctico, razón por la cual surge la inquietud sobre el beneficio de la administración del medicamento en estos pacientes tomando en cuenta que, entre los efectos adversos, se evidencia nefrotoxicidad y ototoxicidad principalmente en personas adultas mayores o con problemas renales previos. Se utilizó la metodología de práctica clínica basada en la evidencia (PCBE), partiendo de una pregunta clínica para posteriormente hacer las búsquedas electrónicas en bases de datos como: MEDLINE, Google académico y Cochrane Library Plus. Después de establecer los criterios de inclusión y exclusión y análisis crítico, se seleccionó cuatro documentos que se relacionan con la respuesta a la pregunta planteada. Los resultados para el análisis crítico fueron revisados minuciosamente a través de la plataforma informática FCL 2.0 con las plantillas correspondientes. La evidencia señala que ningún estudio respondió directamente a la pregunta clínica planteada, las investigaciones analizadas no demuestran evidencia que confirme que el uso profiláctico de la amikacina sea beneficioso en pacientes intervenidos quirúrgicamente. Se concluye que no se encuentró evidencia significativa que respalde el uso profiláctico de la amikacina para disminuir las infecciones. La profilaxis se enfoca en administrar en pacientes sometidos a procedimientos quirúrgicos urológicos como primera elección un antibiótico de menor espectro, ya que para administrar amikacina hay que cumplir con los lineamientos institucionales establecidos según la condición de cada usuario, tomando en cuenta los resultados de las pruebas de función renal pre y post administración.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The aim of this article is to present the best available scientific evidence on the use of amikacin as prophylaxis in patients undergoing prostatectomy. The indication of amikacin in prostatectomy-type surgeries refers to prophylactic use, which is why the concern about the benefit of administering the drug in these patients arises, taking into account that, among the adverse effects, nephrotoxicity and ototoxicity are evidenced mainly in people older adults or with previous kidney problems. We used the evidence-based clinical practice methodology (PCBE), based on a clinical question to later perform the electronic searches in databases such as: MEDLINE, Google academic and Cochrane Library Plus. After establishing the inclusion and exclusion criteria and critical analysis, four documents were selected that relate to the answer to the question posed. The results for the critical analysis were thoroughly reviewed through the FCL 2.0 computer platform with the corresponding templates. The evidence indicates that no study directly responded to the clinical question posed, the investigations analyzed do not demonstrate evidence confirming that the prophylactic use of amikacin is beneficial in patients undergoing surgery. It was concluded that no significant evidence was found to support the prophylactic use of amikacin to reduce infections. Prophylaxis focuses on administering patients with urological surgical procedures as first choice a lower spectrum antibiotic, since to administer amikacin it is necessary to comply with established institutional guidelines according to the condition of each user, taking into account the results of the tests of renal function pre and post administration.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo O objetivo deste artigo é apresentar as melhores provas disponíveis sobre o uso da doença como profilaxia em pacientes com uma prostatectomia. A indicação de amicacina em cirugias tipo prostatectomia é remediada com o uso de profiláctico, a razão pela investigação surge sobre o benefício da administração do medicamento em estágios, a tomada de controle, entre os efetivos adversos, a evidência nefrotoxicidad e ototoxicidad principalmente em personas adultas mayores o com problemas renales previos. Use a metodologia de prática clínica baseada na evidência (PCBE), partindo de uma clínica pré-existente para o futuro sobre as bússulas electrónicas em bases de dados como: MEDLINE, Google académico e Biblioteca Cochrane Plus. Depois de estabelecer os critérios de inclusão e exclusão e análise crítica, selecione o documento que se relaciona com a resposta à pregunta plantada. Os resultados para a análise crítica foram revisados &#8203;&#8203;minuciosamente através da plataforma informática FCL 2.0 com os plantillas correspondentes. A evidência é que o exame é respondido diretamente à consulta clínica plantada, as investigações não demonstram evidências que confirmam o uso profiláctico da amidação do mar em pacientes intervencionados quirúrgicamente. Se concluye que não há provas de que são importantes o uso do termo profiláctico da amicina para disminuir as infecciones. A profilaxia do enfarte na administração de doentes é um procedimento quirúrgico urológico como a primeira eleição do antibiótico de menor espectro, o que ajuda a administrar o feno que cumplir com os lineamentos institucionais estabelecidos segundo a condição de cada um, tomando os resultados dos exames de función renal pré y pós administración.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[amikacina]]></kwd>
<kwd lng="es"><![CDATA[profilaxis]]></kwd>
<kwd lng="es"><![CDATA[prostatectomía]]></kwd>
<kwd lng="en"><![CDATA[amikacin]]></kwd>
<kwd lng="en"><![CDATA[prophylaxis]]></kwd>
<kwd lng="en"><![CDATA[prostatectomy]]></kwd>
<kwd lng="pt"><![CDATA[amicacina]]></kwd>
<kwd lng="pt"><![CDATA[profilaxia]]></kwd>
<kwd lng="pt"><![CDATA[prostatectomia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<collab>Medicine UNLo</collab>
<source><![CDATA[U.S. Department of Health and Human Services National Institutes of Health]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guanche]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pisonero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profilaxis perioperatoria en cirugía urológica en hospitales cubanos]]></article-title>
<source><![CDATA[Revista Cubana de Cirugía]]></source>
<year>2011</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>413-22</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Prevención de las infecciones nosocomiales. Guía práctica. Guía práctica]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[Organización Mundial de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Casares]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Actualización de drogas inyectables]]></source>
<year>2013</year>
<edition>3rd</edition>
<publisher-loc><![CDATA[San José ]]></publisher-loc>
<publisher-name><![CDATA[EDNASSS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Curso Bimodal Práctica Clínica de Enfermería Basada en la Evidencia: Alcances y Limitaciones]]></article-title>
<source><![CDATA[Revenf.]]></source>
<year>2011</year>
<volume>20</volume>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influencia de la capacitación: &#8220;Práctica clínica basada en la evidencia&#8221; en la práctica diaria de la enfermera (o)]]></article-title>
<source><![CDATA[Revenf.]]></source>
<year>2013</year>
<volume>25</volume>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moran]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Práctica de enfermería basada en evidencias]]></article-title>
<source><![CDATA[Revista Mexicana de Enfermería Cardiológica]]></source>
<year>2001</year>
<volume>9</volume>
<numero>1-4</numero>
<issue>1-4</issue>
<page-range>24-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[Satoshi]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum antimicrobial concentrations for surgical antimicrobial prophylaxis in radical nephrectomy and radical prostatectomy]]></article-title>
<source><![CDATA[Journal of Infection and Chemotherapy]]></source>
<year>2015</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[EC at al]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective Korean multicenter study for infectious complications in patients undergoing prostate surgery: risk factors and efficacy of antibiotic prophylaxis]]></article-title>
<source><![CDATA[Journal of Korean medical science]]></source>
<year>2014</year>
<volume>29</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Urologic Surgery Antimicrobial Prophylaxis. Guías clínicas]]></source>
<year>2008</year>
<publisher-loc><![CDATA[USA ]]></publisher-loc>
<publisher-name><![CDATA[American Urological Association]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ammon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Antibiotic stewardship: A crucial task to counter multidrug-resistant bacteria]]></source>
<year>2017</year>
<publisher-name><![CDATA[European Asocciation of Urology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<collab>American Urological Association</collab>
<source><![CDATA[Clinically localized prostate cancer: aua/astro/suo guideline. Guías clínicas de urología]]></source>
<year>2017</year>
<publisher-loc><![CDATA[USA ]]></publisher-loc>
<publisher-name><![CDATA[American Urological Association]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haifler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mor]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dotan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ramon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zilberman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic antibiotic treatment following laparoscopic robot-assisted radical prostatectomy for the prevention of catheter-associated urinary tract infections: did the AUA guidelines make a difference?]]></article-title>
<source><![CDATA[Journal of robotic surgery]]></source>
<year>2017</year>
<volume>11</volume>
<page-range>367-71</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kwon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic Prophylaxis in Radical Prostatectomy: Comparison of 2-Day and More than 2-Day Prophylaxis]]></article-title>
<source><![CDATA[Journal of Korean science]]></source>
<year>2017</year>
<volume>32</volume>
<page-range>1009-15</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<source><![CDATA[Food and Drug Administration]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="book">
<collab>Caja Costarricense de Seguro Social</collab>
<source><![CDATA[Lista oficial de medicamentos (LOM) y normativa CCSS]]></source>
<year>2014</year>
<publisher-loc><![CDATA[San José ]]></publisher-loc>
<publisher-name><![CDATA[BINASS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zúñiga]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bejarano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gough]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chinchilla]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil de sensibilidad a los antibióticos de las bacterias en infecciones del tracto urinario]]></article-title>
<source><![CDATA[Acta Médica Costarricense]]></source>
<year>2016</year>
<volume>58</volume>
<page-range>146-54</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Estrategia mundial de la OMS para contener la resistencia a los antimicrobianos. Guías clínicas]]></source>
<year>2001</year>
<publisher-loc><![CDATA[Suiza ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Richard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variabilidad de la práctica clínica. Situación actual y retos para enfermería]]></article-title>
<source><![CDATA[Enfermería clínica]]></source>
<year>2010</year>
<volume>20</volume>
<page-range>114-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schneidewind]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kranz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schlager]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barski]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mühlsteadt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Grabbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Queissert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Frank]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pelzer]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P]]></article-title>
<source><![CDATA[Central European Journal of Urology]]></source>
<year>2017</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
